Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States
- 1 December 2021
- journal article
- research article
- Published by Elsevier in Ophthalmology
- Vol. 128 (12) , 1699-1707
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 40 references indexed in Scilit:
- Studying Physician Knowledge, Attitudes, and Practices Regarding the Herpes Zoster Vaccine to Address Perceived Barriers to VaccinationCornea, 2013
- Herpes Zoster Eye Complications: Rates and TrendsMayo Clinic Proceedings, 2013
- Herpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort StudyPLOS Medicine, 2013
- Practice Patterns and Opinions in the Management of Recurrent or Chronic Herpes Zoster OphthalmicusCornea, 2012
- Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 YearsClinical Infectious Diseases, 2012
- Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 CountriesAmerican Journal of Epidemiology, 2011
- Herpes Zoster OphthalmicusNatural History, Risk Factors, Clinical Presentation, and MorbidityOphthalmology, 2008
- A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsNew England Journal of Medicine, 2005
- Why Don't Physicians Follow Clinical Practice Guidelines?JAMA, 1999
- Validation of a combined comorbidity indexJournal of Clinical Epidemiology, 1994